These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 27127124

  • 1. The Role of IL-10 Promoter Polymorphisms in Renal Cell Carcinoma.
    Chang WS, Liao CH, Tsai CW, Hu PS, Wu HC, Hsu SW, Ji HX, Hsiao CL, Bau DT.
    Anticancer Res; 2016 May; 36(5):2205-9. PubMed ID: 27127124
    [Abstract] [Full Text] [Related]

  • 2. The Contribution of Interleukin-10 Promoter Genotypes to Susceptibility to Asthma in Adults.
    Hsia TC, Chang WS, Wang S, Shen TC, Hsiao WY, Liu CJ, Liang SJ, Chen WC, Tu CY, Tsai CW, Hsu CM, Bau DT.
    In Vivo; 2015 May; 29(6):695-9. PubMed ID: 26546526
    [Abstract] [Full Text] [Related]

  • 3. Interleukin-10 (IL-10) promoter genotypes are associated with lung cancer risk in Taiwan males and smokers.
    Hsia TC, Chang WS, Liang SJ, Chen WC, Tu CY, Chen HJ, Yang MD, Tsai CW, Hsu CM, Tsai CH, Bau DT.
    Anticancer Res; 2014 Dec; 34(12):7039-44. PubMed ID: 25503130
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Association of interleukin-10 (IL10) promoter genotypes with nasopharyngeal carcinoma risk in Taiwan.
    Tsai CW, Tsai MH, Shih LC, Chang WS, Lin CC, Bau DT.
    Anticancer Res; 2013 Aug; 33(8):3391-6. PubMed ID: 23898109
    [Abstract] [Full Text] [Related]

  • 6. The role of functional polymorphisms of cyclooxygenase 2 in renal cell carcinoma.
    Chang WS, Liao CH, Miao CE, Wu HC, Hou LL, Hsiao CL, Ji HX, Tsai CW, Bau DT.
    Anticancer Res; 2014 Oct; 34(10):5481-6. PubMed ID: 25275044
    [Abstract] [Full Text] [Related]

  • 7. Significant Association of Interleukin-10 Polymorphisms with Childhood Leukemia Susceptibility in Taiwan.
    Lo WJ, Chang WS, Hsu HF, Ji HX, Hsiao CL, Tsai CW, Yeh SP, Chen CM, Bau DT.
    In Vivo; 2016 Oct; 30(3):265-9. PubMed ID: 27107085
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. IL-16 polymorphism and risk of renal cell carcinoma: association in a Chinese population.
    Zhu J, Qin C, Yan F, Wang M, Ding Q, Zhang Z, Yin C.
    Int J Urol; 2010 Aug; 17(8):700-7. PubMed ID: 20529140
    [Abstract] [Full Text] [Related]

  • 14. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma.
    Hirata H, Hinoda Y, Kikuno N, Kawamoto K, Suehiro Y, Tanaka Y, Dahiya R.
    Clin Cancer Res; 2007 Jul 15; 13(14):4123-9. PubMed ID: 17634539
    [Abstract] [Full Text] [Related]

  • 15. The association between three promoter polymorphisms of IL-10 and inflammatory bowel diseases (IBD): a meta-analysis.
    Zou L, Wang L, Gong X, Zhao H, Jiang A, Zheng S.
    Autoimmunity; 2014 Feb 15; 47(1):27-39. PubMed ID: 24128120
    [Abstract] [Full Text] [Related]

  • 16. Candidate genetic modifiers of individual susceptibility to renal cell carcinoma: a study of polymorphic human xenobiotic-metabolizing enzymes.
    Longuemaux S, Deloménie C, Gallou C, Méjean A, Vincent-Viry M, Bouvier R, Droz D, Krishnamoorthy R, Galteau MM, Junien C, Béroud C, Dupret JM.
    Cancer Res; 1999 Jun 15; 59(12):2903-8. PubMed ID: 10383153
    [Abstract] [Full Text] [Related]

  • 17. The involvement of genetic polymorphism of IL-10 promoter in non-small cell lung cancer.
    Shih CM, Lee YL, Chiou HL, Hsu WF, Chen WE, Chou MC, Lin LY.
    Lung Cancer; 2005 Dec 15; 50(3):291-7. PubMed ID: 16122836
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Predictive value of interleukin-10 promoter genotypes and haplotypes in determining the susceptibility to nephropathy in type 2 diabetes patients.
    Mtiraoui N, Ezzidi I, Kacem M, Ben Hadj Mohamed M, Chaieb M, Haj Jilani AB, Mahjoub T, Almawi WY.
    Diabetes Metab Res Rev; 2009 Jan 15; 25(1):57-63. PubMed ID: 19031431
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.